Jacoline E C Bromberg1, Samar Issa2, Katerina Bakunina3, Monique C Minnema4, Tatjana Seute5, Marc Durian6, Gavin Cull7, Harry C Schouten8, Wendy B C Stevens9, Josee M Zijlstra10, Joke W Baars11, Marcel Nijland12, Kylie D Mason13, Aart Beeker14, Martin J van den Bent15, Max Beijert16, Michael Gonzales17, Daphne de Jong18, Jeanette K Doorduijn19. 1. Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: j.bromberg@erasmusmc.nl. 2. Department of Hematology, Middlemore Hospital, Auckland, New Zealand. 3. HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 4. Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands. 5. Department of Neurology, University Medical Center Utrecht, Utrecht, Netherlands. 6. Department of Hematology, ETZ Hospital, Tilburg, Netherlands. 7. Haematology Department, Sir Charles Gairdner Hospital and PathWest Laboratory Medicine, Nedlands, WA, Australia; University of Western Australia, Crawley, WA, Australia. 8. Department of Hematology, University Medical Center, Maastricht, Netherlands. 9. Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands. 10. Department of Hematology, Amsterdam UMC-Vrije Universiteit Amsterdam, Amsterdam, Netherlands. 11. Department of Hemato-Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. 12. Department of Hematology, University Medical Center Groningen, Groningen, Netherlands. 13. Department of Hematology, Royal Melbourne Hospital, Melbourne, VIC, Australia. 14. Department of Hematology, Spaarne Gasthuis, Haarlem, Netherlands. 15. Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 16. Department of Radiotherapy, University Medical Center Groningen, Groningen, Netherlands. 17. Department of Anatomical Pathology, Royal Melbourne Hospital, Melbourne, VIC, Australia. 18. Department of Pathology, Amsterdam UMC-Vrije Universiteit Amsterdam, Amsterdam, Netherlands; HOVON Pathology Facility and Biobank, Amsterdam, Netherlands. 19. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Abstract
BACKGROUND: The prognosis for primary CNS lymphoma has improved with the use of high-dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a chimeric monoclonal antibody that targets the CD20 cell surface protein, has substantial activity in systemic CD20-positive diffuse large B-cell lymphoma, but its efficacy in primary CNS lymphoma is unknown and low penetration of the large rituximab molecule through the blood-brain barrier could limit its effect. We aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary CNS lymphoma. METHODS: This intergroup, multicentre, open-label, randomised phase 3 study was done at 23 hospitals in the Netherlands, Australia, and New Zealand. Non-immunocompromised patients aged 18-70 years with newly diagnosed primary CNS lymphoma were randomly assigned (1:1) to receive methotrexate-based chemotherapy with or without intravenous rituximab. We used a web-based randomisation system with stratification by centre, age, and Eastern Cooperative Oncology Group-WHO performance status, and a minimisation procedure. All group assignment was open label and neither investigators nor patients were masked to allocation. All patients were treated with two 28-day cycles of induction chemotherapy, consisting of intravenous methotrexate 3 g per m2 on days 1 and 15, intravenous carmustine 100 mg per m2 on day 4, intravenous teniposide 100 mg per m2 on days 2 and 3, and oral prednisone 60 mg per m2 on days 1-5, with (R-MBVP) or without (MBVP) intravenous rituximab 375 mg per m2 on days 0, 7, 14, and 21 in cycle one and days 0 and 14 in cycle two. Patients with response at the end of induction subsequently receivedhigh-dose cytarabine and, in patients aged 60 years or younger, low-dose whole-brain radiotherapy. The primary endpoint was event-free survival, with events defined as not reaching complete response or complete response unconfirmed at the end of treatment, or progression or death after response; analysis was adjusted for age and performance score. Patients were analysed on a modified intention-to-treat basis. This trial is registered with the Nederlands Trial Register, number NTR2427, and the Australian New Zealand Clinical Trials Registry, number ACTRN12610000908033. The trial was closed on May 27, 2016, after achieving complete accrual, and follow-up is ongoing. FINDINGS:Between Aug 3, 2010, and May 27, 2016, we recruited 200 patients (109 men and 91 women; median age was 61 years [IQR 55-67]). We randomly assigned 100 patients to MBVP and 99 patients to R-MBVP. One patient was randomly assigned to the R-MBVP group but found to be ineligible because of an incorrect diagnosis and was excluded from all analyses. After a median follow-up of 32·9 months (IQR 23·9-51·5), 98 patients had had an event (51 in the MBVP group and 47 in the R-MBVP group), of whom 79 had died (41 in the MBVP group and 38 in the R-MBVP group). Event-free survival at 1 year was 49% (95% CI 39-58) in the MBVP group (no rituximab) and 52% (42-61) in the R-MBVP group (with rituximab; hazard ratio 1·00, 95% CI 0·70-1·43, p=0·99). Grade 3 or 4 adverse events occurred in 58 (58%) patients in the MBVP group and 63 (64%) patients in the R-MBVP group, with infections (24 [24%] patients receiving MBVP vs 21 [21%] patients receiving R-MBVP), haematological toxicity (15 [15%] vs 12 [12%]), and nervous system disorders (ten [10%] vs 15 [15%]) being the most common. Life-threatening or fatal serious adverse events occurred in 12 (12%) patients in the MBVP group and ten (10%) patients in the R-MBVP group, and five (5%) patients in the MBVP group and three (3%) in the R-MBVP group died from treatment-related causes. INTERPRETATION: We found no clear benefit of addition of rituximab to methotrexate, carmustine, teniposide, and prednisone chemotherapy in primary CNS lymphoma. Therefore, the results of this study do not support the use of rituximab as a component of standard treatment in primary CNS lymphoma. FUNDING: Roche, the Dutch Cancer Society, and Stichting STOPhersentumoren.
RCT Entities:
BACKGROUND: The prognosis for primary CNS lymphoma has improved with the use of high-dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a chimeric monoclonal antibody that targets the CD20 cell surface protein, has substantial activity in systemic CD20-positive diffuse large B-cell lymphoma, but its efficacy in primary CNS lymphoma is unknown and low penetration of the large rituximab molecule through the blood-brain barrier could limit its effect. We aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary CNS lymphoma. METHODS: This intergroup, multicentre, open-label, randomised phase 3 study was done at 23 hospitals in the Netherlands, Australia, and New Zealand. Non-immunocompromised patients aged 18-70 years with newly diagnosed primary CNS lymphoma were randomly assigned (1:1) to receive methotrexate-based chemotherapy with or without intravenous rituximab. We used a web-based randomisation system with stratification by centre, age, and Eastern Cooperative Oncology Group-WHO performance status, and a minimisation procedure. All group assignment was open label and neither investigators nor patients were masked to allocation. All patients were treated with two 28-day cycles of induction chemotherapy, consisting of intravenous methotrexate 3 g per m2 on days 1 and 15, intravenous carmustine 100 mg per m2 on day 4, intravenous teniposide 100 mg per m2 on days 2 and 3, and oral prednisone 60 mg per m2 on days 1-5, with (R-MBVP) or without (MBVP) intravenous rituximab 375 mg per m2 on days 0, 7, 14, and 21 in cycle one and days 0 and 14 in cycle two. Patients with response at the end of induction subsequently received high-dose cytarabine and, in patients aged 60 years or younger, low-dose whole-brain radiotherapy. The primary endpoint was event-free survival, with events defined as not reaching complete response or complete response unconfirmed at the end of treatment, or progression or death after response; analysis was adjusted for age and performance score. Patients were analysed on a modified intention-to-treat basis. This trial is registered with the Nederlands Trial Register, number NTR2427, and the Australian New Zealand Clinical Trials Registry, number ACTRN12610000908033. The trial was closed on May 27, 2016, after achieving complete accrual, and follow-up is ongoing. FINDINGS: Between Aug 3, 2010, and May 27, 2016, we recruited 200 patients (109 men and 91 women; median age was 61 years [IQR 55-67]). We randomly assigned 100 patients to MBVP and 99 patients to R-MBVP. One patient was randomly assigned to the R-MBVP group but found to be ineligible because of an incorrect diagnosis and was excluded from all analyses. After a median follow-up of 32·9 months (IQR 23·9-51·5), 98 patients had had an event (51 in the MBVP group and 47 in the R-MBVP group), of whom 79 had died (41 in the MBVP group and 38 in the R-MBVP group). Event-free survival at 1 year was 49% (95% CI 39-58) in the MBVP group (no rituximab) and 52% (42-61) in the R-MBVP group (with rituximab; hazard ratio 1·00, 95% CI 0·70-1·43, p=0·99). Grade 3 or 4 adverse events occurred in 58 (58%) patients in the MBVP group and 63 (64%) patients in the R-MBVP group, with infections (24 [24%] patients receiving MBVP vs 21 [21%] patients receiving R-MBVP), haematological toxicity (15 [15%] vs 12 [12%]), and nervous system disorders (ten [10%] vs 15 [15%]) being the most common. Life-threatening or fatal serious adverse events occurred in 12 (12%) patients in the MBVP group and ten (10%) patients in the R-MBVP group, and five (5%) patients in the MBVP group and three (3%) in the R-MBVP group died from treatment-related causes. INTERPRETATION: We found no clear benefit of addition of rituximab to methotrexate, carmustine, teniposide, and prednisone chemotherapy in primary CNS lymphoma. Therefore, the results of this study do not support the use of rituximab as a component of standard treatment in primary CNS lymphoma. FUNDING: Roche, the Dutch Cancer Society, and Stichting STOPhersentumoren.
Authors: Tugce Kutuk; G Daniel Grass; Daniel Oliver; Sepideh Mokhtari; Solmaz Sahebjam; Sungjune Kim; Jose Penagaricano; Hsiang-Hsuan Michael Yu; Nam Tran; Arnold Etame; Jennifer L Peterson; Peter Forsyth; Timothy Robinson Journal: Adv Radiat Oncol Date: 2022-03-09
Authors: Mallika P Patel; John P Kirkpatrick; Margaret O Johnson; Patrick Healy; James E Herndon; Eric S Lipp; Elizabeth S Miller; Annick Desjardins; Dina Randazzo; Henry S Friedman; David M Ashley; Katherine B Peters Journal: J Neurooncol Date: 2020-03-05 Impact factor: 4.130
Authors: Matthijs van der Meulen; Linda Dirven; Esther J J Habets; Katerina Bakunina; Marion Smits; Hakim C Achterberg; Tatjana Seute; Gavin Cull; Harry Schouten; Josée M Zijlstra; Dieta Brandsma; Roelien H Enting; Max Beijert; Martin J B Taphoorn; Martin J van den Bent; Samar Issa; Jeanette K Doorduijn; Jacoline E C Bromberg Journal: Neuro Oncol Date: 2021-08-02 Impact factor: 12.300
Authors: Matthijs van der Meulen; Linda Dirven; Katerina Bakunina; Martin J van den Bent; Samar Issa; Jeanette K Doorduijn; Jacoline E C Bromberg Journal: J Neurooncol Date: 2021-02-21 Impact factor: 4.130